Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics
June 21 2017 - 8:30AM
Galectin Therapeutics, Inc. (NASDAQ:GALT), the
leading developer of therapeutics that target galectin proteins,
today announced that the Company has received notice of allowance
for a U.S. Patent for "Galacto-Rhamnogalacturonate compositions for
the treatment of a number of diseases associated with elevated
inducible nitric oxide synthase." The patent’s principal claims
cover method of use for GR-MD-02 in a broad category of diseases in
which there is an inflammatory response characterized by an
increase in the enzyme inducible nitric oxide synthase (iNOS). The
patent covers the reduction in iNOS by GR-MD-02 in a variety of
diseases including autoimmune disease, neurodegenerative disease,
cardiovascular disease, psoriasis, cutaneous and systemic lupus
erythematosus, systemic sclerosis (scleroderma) and dermatitis. The
patent coverage extends through 2032.
This latest patent extends Galectin’s already robust U.S. and
international patent portfolio. Granted patents include composition
of matter, process of manufacture, and various methods of use. The
breadth of coverage for the patent portfolio includes; various
types of organ fibrosis (liver, lung, kidney, and heart),
non-alcoholic steatohepatitis, kidney disease, autoimmune disorders
and cancer, including combination cancer immunotherapy.
"With this patent extending claims to a wide-range of diseases
with an inflammatory response, we now have a broad range of patent
coverage both for diseases in which we currently have developmental
programs, as well as, potential areas of future investigation,"
said Peter G. Traber, M.D., chief executive officer and chief
medical officer of Galectin Therapeutics and inventor on the
patent. "Our patent portfolio is an important asset for Galectin
Therapeutics. Each patent and patent application is a strategic
building block which reflects present and future business
objectives and protects current core technology. Galectin
Therapeutics has multiple additional US and international patent
applications pending."
GR-MD-02, a Non-Biological Complex Drug (NBCD), and a
proprietary polysaccharide pharmaceutical preparation that inhibits
galectin proteins, is currently in a Phase 2b clinical trial in
subjects with NASH cirrhosis and is in preclinical testing for
lung, kidney and cardiovascular fibrosis. GR-MD-02 is also
being studied in combination with Keytruda® and Yervoy®, in two
phase 1b clinical trials at Providence Portland Medical Center for
advanced melanoma, oral neck and head cancer and selected lung
cancer patients. Additionally, GR-MD-02 has been studied and shown
encouraging preliminary results in two, open-label Phase 2a trials
in patients with severe skin diseases, including moderate-to-severe
plaque psoriasis and atopic dermatitis.
About Galectin TherapeuticsGalectin
Therapeutics is developing promising therapies for the treatment of
fibrotic liver disease, skin diseases, and cancer based on the
Company's unique understanding of galectin proteins, which are key
mediators of biologic function. Galectin seeks to leverage
extensive scientific and development expertise as well as
established relationships with external sources to achieve
cost-effective and efficient development. The Company is pursuing a
development pathway to clinical enhancement and commercialization
for its lead compounds in liver fibrosis and cancer. Additional
information is available at www.galectintherapeutics.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements relate to future events or future financial
performance, and use words such as "may," "estimate," "could,"
"expect" and others. They are based on management's current
expectations and are subject to factors and uncertainties that
could cause actual results to differ materially from those
described in the statements. These statements include those
regarding the hope that Galectin's development program for GR-MD-02
will lead to the first therapy for the treatment of fatty liver
disease with cirrhosis and those regarding the hope that our lead
compounds will be successful in connection with cancer
immunotherapy. Factors that could cause actual performance to
differ materially from those discussed in the forward-looking
statements include, among others, that Galectin may not be
successful in developing effective treatments and/or obtaining the
requisite approvals for the use of GR-MD-02 or any of its other
drugs in development; the Company's current clinical trial and any
future clinical studies may not produce positive results in a
timely fashion, if at all, and could prove time consuming and
costly; plans regarding development, approval and marketing of any
of Galectin's drugs are subject to change at any time based on the
changing needs of the Company as determined by management and
regulatory agencies; regardless of the results of any of its
development programs, Galectin may be unsuccessful in developing
partnerships with other companies or raising additional capital
that would allow it to further develop and/or fund any studies or
trials. Galectin has incurred operating losses since
inception, and its ability to successfully develop and market drugs
may be impacted by its ability to manage costs and finance
continuing operations. For a discussion of additional factors
impacting Galectin's business, see the Company's Annual Report on
Form 10-K for the year ended December 31, 2016, and subsequent
filings with the SEC. You should not place undue reliance on
forward-looking statements. Although subsequent events may cause
its views to change, management disclaims any obligation to update
forward-looking statements.
Galectin Therapeutics and its associated logo is a registered
trademark of Galectin Therapeutics Inc.
Contact:
Galectin Therapeutics, Inc.
Jack Callicutt, Chief Financial Officer
678-620-3186
ir@galectintherapeutics.com
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Apr 2023 to Apr 2024